CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy.
about
p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression.Antibody-based immunotherapy for malignant glioma.Prognostic Biomarkers for Hodgkin Lymphoma.Implications of mitogen-activated protein kinase signaling in glioma.Immunostimulation by OX40 Ligand Transgenic Ewing Sarcoma Cells.
P2860
CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
CD137 stimulation and p38 MAPK ...... of glioblastoma immunotherapy.
@en
CD137 stimulation and p38 MAPK ...... of glioblastoma immunotherapy.
@nl
type
label
CD137 stimulation and p38 MAPK ...... of glioblastoma immunotherapy.
@en
CD137 stimulation and p38 MAPK ...... of glioblastoma immunotherapy.
@nl
prefLabel
CD137 stimulation and p38 MAPK ...... of glioblastoma immunotherapy.
@en
CD137 stimulation and p38 MAPK ...... of glioblastoma immunotherapy.
@nl
P2093
P2860
P1476
CD137 stimulation and p38 MAPK ...... of glioblastoma immunotherapy.
@en
P2093
Caspar Kühnöl
Christof Kramm
Jürgen Föll
Monique Herbarth
P2860
P2888
P304
P356
10.1007/S00262-013-1484-9
P577
2013-10-16T00:00:00Z
P6179
1012928059